CeriBell Inc
NASDAQ:CBLL
Profitability Summary
CeriBell Inc's profitability score is hidden . We take all the information about a company's profitability (such as its margins, capital efficiency, free cash flow generating ability, and more) and consolidate it into one single number - the profitability score. The higher the profitability score, the more profitable the company is.
Profitability Score
We take all the information about a company's profitability (such as its margins, capital efficiency, free cash flow generating ability, and more) and consolidate it into one single number - the profitability score. The higher the profitability score, the more profitable the company is.
We take all the information about a company's profitability (such as its margins, capital efficiency, free cash flow generating ability, and more) and consolidate it into one single number - the profitability score. The higher the profitability score, the more profitable the company is.
Profitability Score
Margins
Profit margins represent what percentage of sales has turned into profits. Simply put, the percentage figure indicates how many cents of profit the company has generated for each dollar of sale.
Profit margins help investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Earnings Waterfall
CeriBell Inc
|
Revenue
|
65.4m
USD
|
|
Cost of Revenue
|
-8.7m
USD
|
|
Gross Profit
|
56.8m
USD
|
|
Operating Expenses
|
-96.5m
USD
|
|
Operating Income
|
-39.7m
USD
|
|
Other Expenses
|
-746k
USD
|
|
Net Income
|
-40.5m
USD
|
Margins Comparison
CeriBell Inc Competitors
| Country | Company | Market Cap |
Gross Margin |
Operating Margin |
Net Margin |
||
|---|---|---|---|---|---|---|---|
| US |
C
|
CeriBell Inc
NASDAQ:CBLL
|
579m USD |
87%
|
-61%
|
-62%
|
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
229.3B USD |
56%
|
17%
|
32%
|
|
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
186.2B USD |
67%
|
28%
|
28%
|
|
| US |
|
Boston Scientific Corp
NYSE:BSX
|
155.2B USD |
69%
|
19%
|
12%
|
|
| US |
|
Stryker Corp
NYSE:SYK
|
149.8B USD |
65%
|
22%
|
12%
|
|
| IE |
|
Medtronic PLC
NYSE:MDT
|
114.9B USD |
66%
|
20%
|
14%
|
|
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
51.6B EUR |
39%
|
14%
|
9%
|
|
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
50.3B USD |
45%
|
13%
|
7%
|
|
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
46.3B USD |
79%
|
28%
|
75%
|
|
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
43.2B USD |
61%
|
29%
|
23%
|
|
| US |
|
Resmed Inc
NYSE:RMD
|
37.5B USD |
59%
|
32%
|
26%
|
Return on Capital
Return on capital ratios give a sense of how well a company is using its capital (equity, assets, capital employed, etc.) to generate profits (operating income, net income, etc.). In simple words, these ratios show how much income is generated for each dollar of capital invested.
| Dec 31, 2024 | -21.2% |
| Dec 31, 2023 | 0% |
| Dec 31, 2022 | 0% |
| Dec 31, 2024 | -18% |
| Dec 31, 2023 | 0% |
| Dec 31, 2022 | 0% |
Return on Capital Comparison
CeriBell Inc Competitors
| Country | Company | Market Cap | ROE | ROA | ROCE | ROIC | ||
|---|---|---|---|---|---|---|---|---|
| US |
C
|
CeriBell Inc
NASDAQ:CBLL
|
579m USD |
-21%
|
-18%
|
-19%
|
-133%
|
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
229.3B USD |
31%
|
18%
|
12%
|
21%
|
|
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
186.2B USD |
16%
|
14%
|
15%
|
18%
|
|
| US |
|
Boston Scientific Corp
NYSE:BSX
|
155.2B USD |
10%
|
5%
|
10%
|
8%
|
|
| US |
|
Stryker Corp
NYSE:SYK
|
149.8B USD |
14%
|
7%
|
15%
|
11%
|
|
| IE |
|
Medtronic PLC
NYSE:MDT
|
114.9B USD |
9%
|
5%
|
8%
|
7%
|
|
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
51.6B EUR |
11%
|
4%
|
9%
|
6%
|
|
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
50.3B USD |
6%
|
3%
|
6%
|
5%
|
|
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
46.3B USD |
49%
|
37%
|
15%
|
18%
|
|
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
43.2B USD |
59%
|
27%
|
51%
|
32%
|
|
| US |
|
Resmed Inc
NYSE:RMD
|
37.5B USD |
26%
|
18%
|
25%
|
21%
|
Free Cash Flow
Free cash flow (FCF) is the money a company has left over after paying its operating expenses and capital expenditures. The more free cash flow a company has, the more it can allocate to dividends, paying down debt, and growth opportunities.
If a company has a decreasing free cash flow, that is not necessarily bad if the company is investing in its growth.
| Dec 31, 2024 | -35m |
| Dec 31, 2023 | 0 |
| Dec 31, 2022 | 0 |
| Dec 31, 2024 | -1.6m |
| Dec 31, 2023 | 0 |
| Dec 31, 2022 | 0 |
You don't have any saved screeners yet
